News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
779,696 Results
Type
Article (75973)
Company Profile (507)
Press Release (703216)
Section
Business (219304)
Career Advice (3089)
Deals (37720)
Drug Delivery (114)
Drug Development (88883)
Employer Resources (178)
FDA (17530)
Job Trends (16588)
News (375458)
Policy (37300)
Tag
Academia (2964)
Alliances (55152)
Alzheimer's disease (1325)
Approvals (17426)
Artificial intelligence (146)
Bankruptcy (365)
Best Places to Work (12386)
Biotechnology (335)
Breast cancer (119)
Cancer (1035)
Cardiovascular disease (93)
Career advice (2614)
Cell therapy (240)
Clinical research (69939)
Collaboration (364)
Compensation (177)
COVID-19 (2791)
Data (930)
Diabetes (154)
Diagnostics (6603)
Drug pricing (100)
Earnings (86103)
Employer resources (160)
Events (120487)
Executive appointments (269)
FDA (18007)
Funding (321)
Gene therapy (175)
GLP-1 (676)
Government (4954)
Healthcare (20588)
Infectious disease (2877)
Inflammatory bowel disease (115)
Interviews (566)
IPO (17086)
Job creations (4567)
Job search strategy (2192)
Layoffs (478)
Legal (9332)
Lung cancer (174)
Manufacturing (181)
Medical device (14245)
Medtech (14250)
Mergers & acquisitions (20665)
Metabolic disorders (437)
Neuroscience (1597)
NextGen Class of 2024 (7434)
Non-profit (5026)
Northern California (1299)
Obesity (257)
Opinion (240)
Patents (105)
People (61408)
Pharmaceutical (120)
Phase I (21512)
Phase II (30477)
Phase III (22985)
Pipeline (261)
Postmarket research (3336)
Preclinical (9560)
Radiopharmaceuticals (256)
Rare diseases (212)
Real estate (6880)
Regulatory (24362)
Research institute (2628)
Resumes & cover letters (478)
Southern California (1160)
Startups (4056)
United States (12919)
Vaccines (642)
Weight loss (212)
Date
Today (232)
Last 7 days (972)
Last 30 days (3373)
Last 365 days (37996)
2024 (33076)
2023 (42439)
2022 (53826)
2021 (58599)
2020 (57485)
2019 (50987)
2018 (38821)
2017 (36180)
2016 (36725)
2015 (42837)
2014 (36911)
2013 (33296)
2012 (34834)
2011 (34800)
2010 (34335)
Location
Africa (1099)
Arizona (194)
Asia (46557)
Australia (8065)
California (2998)
Canada (1210)
China (229)
Colorado (136)
Connecticut (142)
Europe (105683)
Florida (422)
Georgia (108)
Illinois (371)
Indiana (199)
Kansas (100)
Maryland (580)
Massachusetts (2522)
Michigan (162)
Minnesota (274)
New Jersey (896)
New York (895)
North Carolina (788)
Northern California (1299)
Ohio (137)
Pennsylvania (792)
South America (1487)
Southern California (1160)
Texas (428)
Washington State (356)
779,696 Results for "johnson and johnson pharmaceutical research and development llc pa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Johnson & Johnson Completes Acquisition of Shockwave Medical
Johnson & Johnson announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech.
May 31, 2024
·
5 min read
Pharm Country
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization
Johnson & Johnson announced a proposed Plan of Reorganization by its subsidiary, LLT Management LLC, for the comprehensive and final resolution of all current and future claims related to ovarian cancer arising from cosmetic talc litigation against it and its affiliates in the United States.
May 1, 2024
·
8 min read
Press Releases
Johnson & Johnson Celebrates Innovation in Regulated RNA and Protein Degradation with 2024 Dr. Paul Janssen Award for Biomedical Research
September 26, 2024
·
5 min read
Deals
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to address significant unmet need in atopic dermatitis (AD).
May 16, 2024
·
8 min read
Press Releases
Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
November 7, 2024
·
38 min read
Pharm Country
Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024
Johnson & Johnson today announced that eight company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking place in Seattle from May 5–9, 2024.
May 3, 2024
·
8 min read
Proteologix, Inc. to be Acquired by Johnson & Johnson
Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson
May 16, 2024
·
2 min read
Press Releases
Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress
October 25, 2024
·
30 min read
Press Releases
Johnson & Johnson Reports Q3 2024 Results
October 15, 2024
·
20 min read
Business
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement with Numab Therapeutics to acquire from Numab’s shareholders its wholly-owned subsidiary for the global rights to a novel, investigational first-in-class bispecific antibody, NM26, in an all-cash transaction of approximately $1.25 billion.
May 28, 2024
·
6 min read
1 of 77,970
Next
